drugset / Trial / NCT05843162
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, randomized, open-label, active comparator-controlled, phase 4 clinical trial to evaluate the blood pressure control of Telmisartan or Losartan in essential hypertensive patients with metabolic syndrome
Timeline
- Start
- 2023-06-01
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Losartan | Other / unclassified | 50 mg | Oral |
| Subject | Telmisartan | Other / unclassified | 40 mg | Oral |
| Background | S-Amlodopine | Unknown | 2.5 mg | Oral |